Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis [Hematologic Malignancy]

Conclusion Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an overall response rate of 73% and complete response rate of 35%.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Clinical Trials, Lymphoma, Chemotherapy, Biologic Therapy Hematologic Malignancy Source Type: research